Immune checkpoint molecules IDO1, FASLG, CD80, HAVCR2, CD73, CTLA-4, LGALS9, VTCN1, TNFRSF14 and PD-L1 may be useful as potential biomarkers for the treatment and prognosis of CCA patients. This evidence concerns the gene CD80 and cholangiocarcinoma.